Psychopharmacology

, Volume 195, Issue 3, pp 425–433

A PET study on regional coexpression of 5-HT1A receptors and 5-HTT in the human brain

  • Johan Lundberg
  • Jacqueline Borg
  • Christer Halldin
  • Lars Farde
Original Investigation

DOI: 10.1007/s00213-007-0928-3

Cite this article as:
Lundberg, J., Borg, J., Halldin, C. et al. Psychopharmacology (2007) 195: 425. doi:10.1007/s00213-007-0928-3

Abstract

Rationale

Several lines of evidence suggest inter-dependency between the serotonin transporter (5-HTT) and the 5HT1A receptor, two recognised targets for the treatment of anxiety and depression.

Objectives

to examine the correlation of regional expression levels for these two serotonergic markers in the human brain in vivo.

Methods

Twelve male control subjects were examined with PET twice on the same day, using the radioligands [11C]WAY 100635 and [11C]MADAM for quantification of the 5-HT1A receptor and the 5-HTT, respectively. The binding potential (BP) was calculated for raphe nuclei, hippocampus and frontal cortex.

Results

In all regions, the BP for both [11C]WAY 100635 (raphe nuclei 1.85–4.71, hippocampus 2.52–6.17, frontal cortex 2.03–3.79) and [11C]MADAM (2.70–7.65, 0.47–1.76, 0.18–0.51) varied several fold between subjects. In the raphe nuclei, where the two markers are situated on the same neurons, the ratio of [11C]WAY 100635 binding to [11C]MADAM BP binding varied considerably (0.43–1.05). There was a positive correlation between the two markers in the raphe nuclei (rxy = 0.68, p < 0.05) and in the hippocampus (rxy = 0.97, p < 0.001) but not in the frontal cortex (rxy = −0.25, p = 0.44).

Conclusions

The results support a correlation between density levels of the 5-HT1A-receptor and the 5-HTT in the raphe nuclei and hippocampus but not in the frontal cortex. A suggested clinical implication is that the inter-individual variability in 5-HT1A-receptor and 5-HTT densities, as well as the ratio of these, is of particular interest in relation to individual responses to selective serotonin reuptake inhibitor treatment.

Keywords

PET5-HT1A-receptor5-HTT[11C]MADAM[11C]WAY 100635HumanIn vivo

Copyright information

© Springer-Verlag 2007

Authors and Affiliations

  • Johan Lundberg
    • 1
    • 2
  • Jacqueline Borg
    • 1
  • Christer Halldin
    • 1
  • Lars Farde
    • 1
  1. 1.Department of Clinical Neuroscience, Section of PsychiatryKarolinska InstitutetStockholmSweden
  2. 2.Department of Clinical Neuroscience, Section of Psychiatry, Psykiatricentrum KarolinskaKarolinska University Hospital SolnaStockholmSweden